Amicus Therapeutics (FOLD)
(Delayed Data from NSDQ)
$10.56 USD
-0.03 (-0.28%)
Updated Oct 3, 2024 04:00 PM ET
After-Market: $10.56 0.00 (0.00%) 4:18 PM ET
3-Hold of 5 3
D Value A Growth A Momentum A VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$10.56 USD
-0.03 (-0.28%)
Updated Oct 3, 2024 04:00 PM ET
After-Market: $10.56 0.00 (0.00%) 4:18 PM ET
3-Hold of 5 3
D Value A Growth A Momentum A VGM
Zacks News
Amicus Therapeutics (FOLD) Surges: Stock Moves 9.2% Higher
by Zacks Equity Research
Amicus Therapeutics (FOLD) saw a big move last session, as its shares jumped more than 9% on the day, amid huge volumes.
Should You Sell Amicus Therapeutics, Inc. (FOLD) Before Earnings?
by Zacks Equity Research
Amicus Therapeutics, Inc. (FOLD) is seeing favorable earnings estimate revision activity as of late, which is generally a precursor to an earnings beat.
Amicus Therapeutics (FOLD) Soars: Stock Adds 9.2% in Session
by Zacks Equity Research
Amicus Therapeutics (FOLD) saw a big move last session, as its shares jumped more than 9% on the day, amid huge volumes.
Options Traders Expect Huge Moves in Amicus Therapeutics (FOLD) Stock
by Zacks Equity Research
Amicus Therapeutics (FOLD) needs Investors to pay close attention to the stock based on moves in the options market lately.
Company News for July 12, 2017
by Zacks Equity Research
Companies in the News are: FOLD,SLP,ARNA,EVGN,MON
Amicus Therapeutics (FOLD) Catches Eye: Stock Jumps 7.3%
by Zacks Equity Research
Amicus Therapeutics, Inc. (FOLD) was a big mover last session, as the company saw its shares rise over 7% on the day.
Amicus Provides Regulatory Update on Fabry Disease Drug
by Zacks Equity Research
Amicus Therapeutics, Inc. (FOLD) issued an update on the regulatory pathway for migalastat for the treatment of Fabry disease in the U.S.